Ginsenoside Rd promotes glutamate clearance by up-regulating glial glutamate transporter GLT-1 via PI3K/AKT and ERK1/2 pathways

Xiao Zhang1, Ming Shi1, Magnus Bjørås2, Wei Wang2, Guangyu Zhang1, Junliang Han1, Zhirong Liu1, Yunxia Zhang1, Bing Wang1, Jing Chen1, Yi Zhu1, Lize Xiong1 and Gang Zhao1**

1 Department of Neurology, Xijing Hospital, The Forth Military Medical University, Xi’an, Shaanxi, China
2 Department of Microbiology, Institute of Clinical Medicine, Oslo University Hospital, Oslo, Norway
3 Department of Anesthesiology, Xijing Hospital, The Forth Military Medical University, Xi’an, Shaanxi, China

**Correspondence: Gang Zhao, Department of Neurology, Xijing Hospital, The Forth Military Medical University, Xi’an, Shaanxi 710032, China
E-mail: zhaogang@fmmu.edu.cn

INTRODUCTION

In spite of advances in technology and improved clinical care, ischemic stroke still remains a major cause of mortality and disability in human and the second leading cause of death in developed countries (Coldstein et al., 2016). Two major approaches have been developed to treat acute ischemic stroke: recanalization and neuroprotection (Gropen et al., 2006). The goal of neuroprotective therapy is to save potentially viable brain tissue in the ischemic penumbra. Unfortunately, although many neuroprotective interventions are effective for stroke in the animal model, they failed to benefit to patients in clinical trials. Thus, developing effective drugs to treat acute ischemic stroke still faces challenges.

Ginseng, the root of Panax ginseng C. A. Meyer (Araliaceae), has been widely used as a kind of traditional Chinese herbal medicine for 1000s of years. Ginsenosides are the most active ingredients in ginseng. Up to now more than 40 different ginsenosides, including ginsenoside Rd (Rd) have been identified (Radad et al., 2006). Our randomized, double-blind, placebo-controlled, multicenter trial showed that Rd is effective and safe for the treatment of acute ischemic stroke (Liu et al., 2009, 2012). In our pre-clinical studies, we found that Rd can prevent glutamate/oxygen–glucose deprivation (OGD)-induced apoptosis in cultured neurons (Ye et al., 2009; Li et al., 2010), and reduce infarction volume after transient focal ischemia in rats (Ye et al., 2011a,b), suggesting that Rd can be served as a promising neuroprotectant. However, the underlying mechanisms of Rd neuroprotection are still not fully elucidated. Numerous approaches in neuroprotection have considered the application aimed at targeting non-neuronal cells (Van der Schyf et al., 2006). Besides directly supporting neurons, Rd can interfere with a number of other cells such as astrocytes (Lopez et al., 2007). Astrocytes play an important role in supporting neurons in physiological and pathological conditions by producing various growth factors. Particularly, they are the key cells for the uptake of excitatory neurotransmitter glutamate (Danbolt, 2001). Excessive extracellular glutamate elicits neurotoxicity and is mainly removed by glutamate transporters, GLAST (EAA1T1) and GLT-1 (EAA1T2), exclusively expressed on astrocytes (Gegelashvili and Schousboe, 1997). GLT-1 is indispensable for neuronal survival after stroke. Here we investigated the effects of Rd on the levels of extracellular glutamate and the expression of GLT-1 in vivo and in vitro. After rat middle cerebral artery occlusion, Rd significantly increased the mRNA and protein expression levels of GLT-1, and reduced the burst of glutamate as revealed by microdialysis. Consistently, specific glutamate uptake by cultured astrocytes was elevated after Rd exposure. Furthermore, we showed that Rd increased the levels of phosphorylated protein kinase B (PKB/Akt) and phospho-ERK1/2 (p-ERK1/2) in astrocyte culture after oxygen–glucose deprivation. Moreover, the effect of Rd on GLT-1 expression and glutamate uptake can be abolished by PI3K/AKT agonist LY294002 or ERK1/2 inhibitor PD98059. Taken together, our findings provide the first evidence that Rd can promote glutamate clearance by up-regulating GLT-1 expression through PI3K/AKT and ERK1/2 pathways.

Keywords: ginsenoside Rd, GLT-1, astrocyte, glutamate, PI3K/AKT, ERK1/2
in this study we investigated the effects of Rd on extracellular glutamate metabolism and the expression of GLT-1, and further explored whether PI3K/AKT and ERK1/2 pathways were involved in this process.

MATERIALS AND METHODS

MATERIALS

Rd with a purity of 98% was obtained from Tai-He Biopharmaceutical Co. Ltd. (Guangzhou, China). The stock solutions were prepared in saline containing 10% 1,3-propanediol (v/v). Hoechst 33342 was purchased from Sigma–Aldrich Inc. (St. Louis, MO, USA). The commercial kit for the detection of glutamate was purchased from CMA (Solna, Sweden). GLT-1 antibody was obtained from Abcam (Cambridge, UK) and other antibodies were purchased from Cell Signaling (Danvers, MA, USA). All other reagents were from commercial suppliers and of standard biochemical quality.

FOCAL CEREBRAL ISCHEMIA

Male Sprague–Dawley rats weigh 270–320 g were used in this study. Animal protocols were approved by the Ethics Committee for Animal Experimentation of the Fourth Military Medical University. The focal cerebral ischemia was induced by 1.5 h of middle cerebral artery occlusion (MCAO) as described previously with some modifications (Kramer et al., 2010). In brief, animals were anesthetized with a mixture of isoflurane (1.5–2%), oxygen and nitrogen. Body temperature in the rectum was maintained at 37°C using a thermostatically controlled heating blanket connected to a thermometer probe. A 4-0 nylon monofilament coated with poly-L-lysine was introduced through the internal carotid artery to occlude the origin of the middle cerebral artery (MCA). The induction of focal cerebral ischemia was verified with laser Doppler flowmetry (PeriFlux 5000; Perimed AB, Sweden). A drop in regional cerebral blood flow (CBF) below 30% from baseline after the insertion of the filament was considered to be sufficient for induction of focal cerebral ischemia. Control animals were subjected to the same surgical procedures except that the suture was not advanced into the MCA. Rd with a concentration of 30 mg/kg or vehicle was applied intraperitoneally 1 h before MCAO. Animals were sacrificed at designated times points after MCAO and samples were collected for Western blot and reverse transcription polymerase chain reaction (RT-PCR) experiments analysis. The tissues from the ischemic core and penumbra were dissected according to the protocol described by Kramer et al. (2010).

ASTROCYTE CULTURES

Astrocytes were cultured from newborn Sprague-Dawley rats as previously described with some modifications (Lopez et al., 2003; Pawlak et al., 2005). Briefly, a microdialysis probe (BAS MD-2204, 4 mm membrane) was stereotaxically inserted into the right striatum through the cannula guide (-3 mm anteroposterior, +4 mm mediolateral to the Bregma, -4 mm dorsoventral from the surface of the brain). Artificial cerebrospinal fluid (NaCl 135 mM, KCl 1 mM, CaCl2 1.2 mM, MgCl2 1 mM, pH 7.4) was perfused at 2 μl/min using a microinjection pump (BeeHive BAS, USA). The microdialysis samples were continuously collected into microvials collected every 20 min. Three samples were collected as baseline values at the end of 2 h equilibration period. The concentrations of glutamate in the microdialysis samples were determined using a CMA 600 Analyzer (Solna, Sweden). Level changes for all measured chemicals were expressed as percent relative to the mean baseline value.

EVALUATION OF GLUTAMATE UPTAKE

Extracellular glutamate levels were measured by a fluorometric method using the Amplex Red Glutamic Acid assay kit (Invitrogen) as described previously with some modifications (Sato et al., 2003; Pawlak et al., 2005). After 3 h of OGD, astrocyte culture medium was replaced with Hepes buffer containing 25 mM glucose and 500 μM glutamate. At each time point, 50 μl of supernatants was transferred into 96-well microplates, and then mixed with 50 μl substrate mixture (100 mM Amplex Red, 0.25 U/ml horse radish peroxidase, 0.08 U/ml L-glutamate oxidase, 0.5 U/ml glutamate pyruvate transaminase, and 200 μl alamine) and incubated at 37°C for 30 min. Fluorescence was measured using an automated microplate reader at a wavelength of 530 nm (vs. reference wavelength of 590 nm). Glutamate concentrations were calculated from the standard curve with known glutamate amounts.

IMMUNOCYTOCHEMISTRY

Immunofluorescence labeling was performed as described (Plachzer et al., 2004). Cultured cells were fixed with 4% (w/v) paraformaldehyde for 20 min and then washed with phosphate buffered saline (PBS). The cells were permeabilized with 0.1% Triton X-100 in PBS for 1 h at room temperature. After blocked with bovine serum albumin (BSA) for 30 min, the cultures were incubated with primary antibody (GLT-1 1:100) in PBS containing 0.5% (w/v) BSA and 0.1% triton X-100 at 4°C overnight. After washed with PBS for three times, the cultures were incubated with biotinylated anti-rabbit IgG (1:200) for 2 h, followed by streptavidin–cy3 (1:1000) for 2 h. Hoechst 33342 (1 μg/ml) was used for counterstain. The immunostaining images were observed under a fluorescence microscope (Leica, Germany).
REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION

Brain tissues were collected at 24 h following MCAO. RT-PCR was performed as described (Puvvaldi et al., 2005). Total RNA of brain tissues was extracted using Triozol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions. 3 μg of total RNA was used for reverse transcription using Revert Aid First Strand cDNA Synthesis Kit (Fermentas, Burlington, ON, Canada). The PCR amplification was carried out as follows: a 30 min incubation at 58°C for cDNA synthesis, a 3 min hot start at 94°C followed by 32 cycles of denaturation at 94°C for 30 s, annealing at 56°C for 30 s, and extension at 72°C for 30 s with a final extension at 72°C for 5 min. The amplified products were electrophoretically separated by 1.5% agarose gels containing ethidium bromide. Data were normalized to β-actin expression. Forward/reverse primers were:

\[
\text{GTL-1: 5'-CAAGGCTGAGTGAGGTTCTT-3'}/5'-CCACCATCCACACAGTGAC
\]

\[
\text{GAPDH: 5'-TGTGGCA TCCA TGAAACT AC-3'}/5'-CACGCTTG GAATG TGACC-3'
\]

**WESTERN BLOT**

Tissue of interest was homogenized on ice in the RIPA lysis buffer (Beyotime, China) containing 0.5 mM phenylmethylsulfonyl fluoride (PMSF). Western blot was performed according to Ye et al. (2011b). Briefly, protein samples were electrophoresed on a 10% SDS-PAGE and subsequently transferred to polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA, USA). The membrane was incubated in blocking buffer at room temperature for another 1 h. Secondary antibody at room temperature for another 1 h. The membrane was washed three times with TBST (Tris-buffered saline (TBS) and 0.1% Tween 20) and then incubated with the primary antibody [GLT-1 at 1:100; p-AKT at 1:500; p-ERK at 1:500; ERK at 1:1000; AKT at 1:1000, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) at 1:2000] in blocking buffer at 4°C overnight. The membrane was washed three times with TBST (tris-buffered saline (TBS) and 0.1% Tween 20) and then incubated with horseradish peroxidase (HRP)-conjugated secondary antibody at room temperature for another 1 h. Specific signals of proteins were visualized by chemiluminescence using the enhanced chemiluminescence (ECL) western blotting detection system (GE Healthcare, UK). For quantitative analysis, the ratio of the specific signals of protein (relative intensity of the signal) to that of GAPDH protein was calculated.

**STATISTICAL ANALYSIS**

All results were presented as mean with standard error mean (SEM). Microdialysis and glutamate uptake results were analyzed with repeated-measures analysis of variance, followed by Tukey HSD post hoc test. Other results were analyzed using one-way ANOVA followed by Tukey HSD post test for multiple comparisons. Origin pro 8 software was used for statistical tests. Statistical significance was established at p < 0.05.

**RESULTS**

Rd PROMOTES GLUTAMATE CLEARANCE IN VITRO AND IN VIVO

To determine the effects of Rd on extracellular glutamate metabolism in vivo, we measured concentrations of extracellular glutamate during the period of 1.5 h ischemia and 2.5 h reperfusion in the ischemic striatum. As shown in Figure 1A, MCAO induced a rapid and marked increase in levels of extra-cellular glutamate, which reached the maximum at 60–100 min after stroke onset. The concentration of glutamate decreased after reperfusion but did not return to the basal lines during the measurement period in MCAO group. Compared with MCAO group, Rd administration 1 h before MCAO attenuated glutamate burst and promoted its recovery to the baseline 150 min after reperfusion. The differences in glutamate levels between MCAO and Rd-treated rats were significant at 100, 120, 140, and 160 min of occlusion (Figure 1A).

Furthermore, the effect of Rd on astrocyte glutamate uptake was evaluated by the quantification of the clearance of exogenous glutamate (500 μM) from the astrocytes culture medium. Following 3 h of OGD insult, extracellular glutamate levels in the medium from cultured astrocytes with or without Rd pre-treatment (1, 10, and 50 μM, 12 h before OGD) were examined at different
time intervals. 10 and 50 μM Rd significantly enhanced the glutamate uptake in astrocyte cultures, compared with the control (Figure 1B).

**Rd Up-regulates GLT-1 Expression After MCAO**

Since GLT-1 is one of the main transporters for removal of extracellular glutamate accumulation, we next investigated whether Rd could affect GLT-1 expression during and after rat MCAO (Figure 2). Western blotting results showed that GLT-1 protein levels were reduced 4 and 24 h after MCAO in both core and penumbra of ischemic rat brains, consistent with previous reports (Chen et al., 2005; Han et al., 2008). Rd treatment up-regulated GLT-1 expression at both time points after rat MCAO (Figures 2A–D). Similarly, RT-PCR analysis also showed an increase in mRNA expression levels of GLT-1 in the presence of Rd 24 h after MCAO (Figures 2E,F), suggesting that Rd up-regulates GLT-1 expression after MCAO.

**Rd Increases the Levels of Phospho-PI3K/AKT and Phospho-ERK1/2**

PI3K/AKT and ERK mediate crucial regulatory pathways of cell survival (Kumar et al., 2004; Liu et al., 2012a). Both pathways are known to induce GLT-1 expression (Li et al., 2006; Lee et al., 2012a). We then explored whether Rd-induced GLT-1 up-regulation was mediated through PI3K/AKT and/or ERK pathway in astrocyte culture subjected to OGD insult. Western blotting showed that the levels of phospho-AKT and phospho-ERK were reduced 6 and 12 h after OGD, consistent with previous reports (Liu et al., 2012a; Xie et al., 2012; Xu et al., 2012). After the treatment of Rd, the levels of phosphorylation of AKT and ERK were
PI3K/AKT AND ERK1/2 PATHWAYS ARE INVOLVED IN Rd ENHANCED GLT-1 EXPRESSION AND GLUTAMATE UPTAKE

Finally, we investigated whether Rd-induced GLT-1 up-regulation and glutamate uptake enhancement was mediated by PI3K/AKT and ERK1/2 pathways by using PI3K/AKT pathway inhibitor LY294002 or ERK1/2 pathway inhibitor PD98059. Western blotting and immunofluorescence labeling results showed that GLT-1 protein levels in cultured astrocytes decreased 12 h after OGD (Figure 4A). Similar to MCAO results, Rd increased GLT-1 expression 6 h (data not shown) and 12 h after OGD. While pre-treatment with LY294002 or PD98059 inhibited these effects of Rd (Figure 4B). Next, we tested the role of PI3K/AKT and ERK in Rd-induced glutamate uptake. As expected, Rd promoted astrocyte glutamate clearance, which can be abolished by co-treatment with LY294002 or PD98059 (Figure 4C). Taken together, these results suggest that Rd may promote GLT-1 expression and glutamate uptake through PI3K/AKT and ERK1/2 pathways.

DISCUSSION

In the present study, we investigated the effects of Rd on the expression of the astrocytic glutamate transporter GLT-1 as well as glutamate uptake activity in cultured astrocytes and MCAO rat. The results showed that Rd increased mRNA and protein levels of GLT-1. This effects can be inhibited by the AKT or ERK1/2 inhibitor, suggesting that AKT and ERK1/2 signaling pathways are involved in Rd-mediated effects on extracellular glutamate metabolism.

Glutamate-induced excitotoxicity is an important factor responsible for cell death in many central nervous system (CNS) disorders (Benveniste et al., 1984). Excessive extracellular glutamate over-stimulates ionotropic GluRs, such as NMDA,
FIGURE 4 | PI3K/AKT and ERK are involved in Rd-induced GLT-1 up-regulation and glutamate uptake enhancement. 20 μM PD0325901 (PD) or 5 μM U0126 (LY) was pre-treated 12 h before OGD. (A) Double immunofluorescence labeling (GLT-Red, Hoechst-blue) 12 h after OGD. (B) Western blotting results 12 h after OGD. (C) Glutamate uptake assays. After 3 h of OGD, 500 μM glutamate was added to medium, and glutamate concentrations were measured at different time intervals (from 2 to 12 h after OGD washout). Data are expressed as mean ± SEM (n=6). Mean values in sham-treated groups were scaled to 100%. *p < 0.05 vs. OGD + Rd group.

subsequently initiating a series of downstream lethal events including oxidative stress, mitochondrial dysfunction, and inflammation (Szydlowska and Tymianski, 2010). Astrocytes play a crucial role in the removal of extracellular glutamate to prevent against glutamate excitotoxicity (Rothstein et al., 1996). Two types of glutamate transporters, GLAST and GLT-1, are identified in astrocytes: GLAST is predominantly expressed in the cerebellum and required to keep extracellular glutamate at a physiological level (Watase et al., 1998). GLT-1 is abundant in various area of the forebrain, including hippocampus, cerebral cortex, and the striatum. It is responsible for more than 90% of glutamate uptake in these areas (Danbolt, 2001). A group of studies have showed that GLT-1 is required for uptake of extracellular glutamate to protect neurons under ischemic conditions. For example, knockdown of GLT-1 expression exacerbated ischemia-induced neuronal damage and causes enlarged infarct volume (Rao et al., 2001). In contrast, targeted overexpression of GLT-1 decreased the glutamate overflow and reduced the cellular and behavioral deficits induced by ischemic stroke (Harvey et al., 2011). Thus, GLT-1 plays a neuronal protective role during ischemic stroke. Several studies showed decreases in GLT-1 mRNA and protein levels in the rat brain following ischemic insult (Kumar et al., 2004; Liu et al., 2012a). Glutamate release in less severely ischemic brain was shown to occur mainly via volume-activated anion channels but not via GLT-1 reversal (Feustel et al., 2004). These studies suggest that GLT-1 reversal may not be an essential mechanism for increased extracellular glutamate concentration, particularly in ischemic penumbra.

As critical mediators, AKT and ERK1/2 signaling pathways are involved in cell proliferation, differentiation, and adaptation (Kumar et al., 2004; Liu et al., 2012a). Phosphorylation of ERK1/2 and AKT activates the transcription factors, NF-κB, and cAMP-response element binding protein (CREB), which in turn control the transcription of GLT-1 (Li et al., 2006; Lee et al., 2012a). In addition, other types of ginsenosides, such as Rb1, Rg1, have been reported to affect AKT and ERK1/2 pathways (Lan et al., 2011; Hashimoto et al., 2012; Yan et al., 2013). Our present study further showed that Rd activated AKT and ERK1/2 signaling pathways (Figure 4), subsequently affecting GLT-1 expression and extracellular glutamate uptake.

Estrogen receptor (ER)-mediated PI3K/AKT and ERK1/2 activation are well-documented in protection against cell death. Recently, several reports showed that ER activation increased GLT-1 expression and glutamate uptake (Lee et al., 2012a,b).
Ginseng has been recommended for alleviation of the symptoms of menopause, indicating that some components of ginseng act as phytosterogens via activation of the ER (Amato et al., 2002). Some evidence showed that ginseng extracts were able to stimulate the growth of ER-positive cells (Duda et al., 1999). Ginsenosides were structurally and functionally similar to 17β-estradiol (Lee et al., 2003; Lau et al., 2008) and showed AKT and ERK1/2 activation and sequential GLT-1 up-regulation. Yet, Rd may also affect the functions of GLT-1 in several ways, including cell trafficking, splicing, and post-translational modification. Thus, the possible links between Rd and ER still require further clarification.

In summary, in the present study we showed that Rd could promote extracellular glutamate clearance by up-regulating GLT-1 expression through PI3K/AKT and ERK/12 pathways.

ACKNOWLEDGMENTS

The authors are grateful to Ms. Dongyun Feng for technical assistance. This work was supported by grants from Science and Technology project of Shaanxi Province (2013k12-01-02).

AUTHOR CONTRIBUTIONS

Xiao Zhang: most of the research work and paper writing. Ming Shi: part of the paper writing and experiment design. Magnar Bjørk: polishing manuscript, great assistance in main research project design. Wei Wang: paper revision, great assistance in experiment design. Guangyun Zhang: funds support. Junliang Shi: great assistance in Microdialysis experiment. Zhizhong Liu: great assistance in experiment design. Yunxia Zhang: doing part of the Western blot experiment. Bing Wang: doing part of the Immunoblot experiment. Jing Chen: glial cultures and OGD experiment. Yi Zhu: doing the animal surgery. Lize Xiong: main research project design. Gang Zhao: main research project and experiment design.

REFERENCES

Amato, P., Christophie, S., and Millon, P. L. (2002). Estrigenic activity of herbs up-regulating GLT-1 expression through PI3K/AKT and ERK pathways (Lan et al., 2011; Hashimoto et al., 2012; Yan et al., 2013). Thus, we proposed that acting on ER may account for Rd-induced AKT and ERK1/2 activation and sequential GLT-1 up-regulation. Yet, Rd may also affect the functions of GLT-1 in several ways, including cell trafficking, splicing, and post-translational modification. Thus, the possible links between Rd and ER still require further clarification.

In summary, in the present study we showed that Rd could promote extracellular glutamate clearance by up-regulating GLT-1 expression through PI3K/AKT and ERK/12 pathways.

ACKNOWLEDGMENTS

The authors are grateful to Ms. Dongyun Feng for technical assistance. This work was supported by grants from Science and Technology project of Shaanxi Province (2013k12-01-02).

AUTHOR CONTRIBUTIONS

Xiao Zhang: most of the research work and paper writing. Ming Shi: part of the paper writing and experiment design. Magnar Bjørk: polishing manuscript, great assistance in main research project design. Wei Wang: paper revision, great assistance in experiment design. Guangyun Zhang: funds support. Junliang Shi: great assistance in Microdialysis experiment. Zhizhong Liu: great assistance in experiment design. Yunxia Zhang: doing part of the Western blot experiment. Bing Wang: doing part of the Immunoblot experiment. Jing Chen: glial cultures and OGD experiment. Yi Zhu: doing the animal surgery. Lize Xiong: main research project design. Gang Zhao: main research project and experiment design.

REFERENCES

Amato, P., Christophie, S., and Millon, P. L. (2002). Estrigenic activity of herbs commonly used as remedies for menopausal symptoms. Menopause 9, 145–150. doi: 10.1097/00016647-200203000-00010

Bembenek, H., Dvorsky, J., Schwebos, A., and Dames, N. H. (1984). Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischaemia monitored by intracerebral microdialysis. J Neurochem. 43, 1369–1374. doi: 10.1111/j.1471-4159.1984.tb07086.x

Chen, J. C., Hsu-Chen, H., Liu, J. L., Chuang, Y. C., Huang, H. M., Wang, H. L., et al. (2005). Down-regulation of the glutamate transporter GLT-1 in rat hippocampus and striatum and its modulation by a group III metabotropic glutamate receptor agonist following transient global forebrain ischaemia. Neuropharmacology 49, 703–714. doi: 10.1016/j.neuropharm.2005.08.002

Danbolt, N. C. (2001). Glutamate uptake. Prog. Neurobiol. 65, 101–115. doi: 10.1016/S0301-0082(00)00067-8

Duda, R. B., Zhong, Y., Navas, V., Li, M. Z., Toy, B. R., and Alvarez, J. G. (1999). American ginseng and breast cancer therapeutic agents synergistically inhibit MCF-7 breast cancer cell growth. J Surg Oncol. 68, 463–468. doi: 10.1002/(SICI)1096-9098(199912)72:4<230::AID-JSO9>3.0.CO;2-2

Evid. Based Complement. Alternat. Med. 2012, 693717.

Gagliano, P. J., Blake, C. A., Sacco, R. L., Kwiatkowski, T., Goldstein, L. B., Adams, R., Alberts, M. J., Appel, L. J., Brass, L. M., Bushnell, C. D., Chen, K., Cui, T., DeMott, J., et al. (2011). Targeted over-expression of glutamate transporter 1 (GLT-1) reduces ischemic brain injury in a rat model of stroke. PLoS ONE 6, e22135. doi: 10.1371/journal.pone.0022135

Hashimoto, R., Yu, I., Konzumi, H., Usui, Y., and Ochi, T. (2012). Ginsenoside Rd prevents MPP+ -induced apoptosis in PC12 cells by stimulating astrocyte glutamate receptors with consequent activation of ERK1/2. Aki and inhibition of SAPK/JNK, p38 MAPK. J. Peptide and Protein Res. 1, 1–10. doi: 10.1161/01.STR.0000124127.57946.a1

J. Steroid Biochem. Mol. Biol. 82, 148–155. doi: 10.1016/j.jsbmb.2007.05.003

Lee, E., Saylor-Wigmoregny, M., Wang, N., Webb, A., Li, S. D., Luo, K., et al. (2012a). GEFH regulates glutamate transporter Glt-1 expression in rat primary astrocytes. J. Biol. Chem. 287, 26817–26828. doi: 10.1074/jbc.M112.434067

Lee, E., Saylor-Wigmoregny, M., Yim, Z., Webb, A., Li, S. D., and Aschner, M. (2012b). Transforming growth factor-alpha mediates oxygen-induced up-regulation of glutamate transporter GLT-1 in rat primary astrocytes. Cell 60, 1024–1036. doi: 10.1022/235239

Lee, Y., Lin, Y., Liu, W., Wu, X., Shen, J., Gierman, W. J., et al. (2005). A ginsenoside-Rb1, a component of ginseng saponins, activates estrogen receptor in human breast carcinoma MCF-7 cells. J. Steroid Biochem. Mol. Biol. 94, 465–468. doi: 10.1016/j.jsbmb.2004.09.005

Li, L., Bi, T., Tian, S. V., Zidenara, O., Watson, D. I., Wolfe, J. H., Rothstein, J. D., et al. (2006). Regulation of astrocytic glutamate transporter expression by Akt: evidence for a selective transcriptional effect on the GLT-1/EAA T2 subtype. J. Neurochem. 97, 739–771. doi: 10.1111/j.1471-4159.2005.03745.x

Li, X., Liang, J., Tang, Y. B., Zhou, J. G., and Guan, Y. T. (2015). Ginsenoside Rd prevents glutamate-induced apoptosis in rat cortical neurons. Clin Exp Pharmacol Physiol. 42, 199–204. doi: 10.1111/cepp.12586

Lin, R., Xing, Q. J., Shi, Q., Wu, W. N., Cheng, J., Fu, H., et al. (2012a). Hypoxia protects cortical neurons from oxygen-glucose deprivation-exposure-induced injury via nitric oxide signaling pathway. Brain Res. 1469, 164–173. doi: 10.1016/j.brainsci.2012.08.004

Lin, X., Wang, L., Wen, A., Yang, J., Yan, Y., Song, Y., et al. (2012b). Ginsenoside-Rd improves outcome of acute ischemic stroke - a randomised, double-blind, placebo-controlled, multicenter trial. Eur J Neurol. 19, 875–885. doi: 10.1111/j.1468-1331.2011.03044.x

Prog. Neurobiol.
Liu, X., Xia, J., Wang, L., Song, Y., Yang, J., Yan, Y., et al. (2009). Efficiency and safety of ginsenoside-Rd for acute ischemic stroke: a randomized, double-blind, placebo-controlled, phase II multicenter trial. *Eur. J. Neurol.* 16, 589–597. doi: 10.1111/j.1468-1331.2009.02534.x

Lopiet, M. N., Guadalupe, M. F., Ruiz-Peña, O. M., De Frons, A. M., and Acuña, M. E. (2007). Neuroprotective effect of individual ginsenosides on astrocyte primary culture. *Biokim. Biophys. Acta 1770*, 1308–1316. doi: 10.1016/j.bbagen.2007.06.008

Mittag, A., and Tanaka, K. (2003). Functional changes of glial glutamate transporter GLT-1 during ischemia in an in vivo study in the hippocampal CA1 of normal mice and mutant mice lacking GLT-1. *J. Neurosci.*, 23, 7717–7726.

Pandol, J., Brin, V., Kappas, E., and Boyer, C. (2005). Regulation of glutamate transporter GLAST and GLT-1 expression in astrocytes by estrogen. *Brain Res. Mol. Brain Res.* 138, 1–7. doi: 10.1016/j.molbrain.2004.10.043

Philipp, J. W., Ben, J., and O’Rajun, M. H. (2006). Transporter reversal as a mech-anism of glutamate release from the ischemic rat cerebral cortex: studies with DL-threo-beta-benzyloxyaspartate. *Brain Res.* 880, 224. doi: 10.1016/S0006-8993(06)02274-4

Plachey, C., Martin, A., Gutmann, J., and Reichen, M. (2004). Astrocytes repress the neuronal expression of GLAST and GLT glutamate transporters in cultured hippocampal neurons from embryonic rats. *Neuroreport.* 15, 1115–1123. doi: 10.1097/01.wnr.0000128119.03413.39

Rafal, K., Gils, G., Liu, L., and Rausch, W. D. (2006). Use of ginseng in medicine with emphasis on neurodegenerative disorders. *J. Pharmacol. Sci.* 100, 175–186. doi: 10.1254/jphs.CRP05015X

Rao, V. L., Dogan, A., Todd, K. G., Bowen, K. K., Kim, B. T., Rothstein, J. D., Roettger, V., and Lipton, P. (1996). Mechanism of glutamate release from rat hippocampal slices during in vitro ischemia. *Neuroscience* 75, 677–685. doi: 10.1016/0306-4522(96)00314-4

Reithman, J. D., Dyko-Huberg, M., Pardo, C. A., Britell, L. A., Jin, L., Kanal, B. W., et al. (1996). Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. *Neuron* 16, 675–686. doi: 10.1016/0896-6273(96)80008-8

Sato, K., Mietzsch, N., Ohara, Y., and Nakazawa, K. (2003). Estrogen inhibits glutamate uptake activity of astrocytes via membrane estrogen receptor alpha. *J. Neurosci.* 23, 1498–1505. doi: 10.1523/JNEUROSCI.0401-03.2003

Szedowska, K., and Tymianski, M. (2010). Calcium, ischemia and excitotoxicity. *Gig. Calcif. Dev.* 47, 122–129. doi: 10.1616/j.cce.2010.01.003

Van der Schyf, C. J., Geldenhuys, W. J., and Yousim, M. B. (2006). Multifunctional *Nature.* 445, 956–958. doi: 10.1038/nature05428

Xie, R., Li, X., Long, Y., Shen, C., Wu, X., Xia, W., et al. (2012). Alpha-lipoic acid pre- and post-treatments provide protection against in vitro ischemia-reperfusion injury in cerebellar endothelial cells via Akt/mTOR signaling. *Brain Res.* 1482, 81–90. doi: 10.1016/j.brainres.2012.09.009

Xu, C., Li, L., Zhang, G., Li, B., Gao, L., and Sun, Y. (2012). Neuronal biotin protects oligodendrocyte progenitor cells from oxygen/glucose deprivation injury induced apoptosis via ErbB-dependent activation of PI3-kinase/Akt. *Brain Res.* 1407, 104–112. doi: 10.1016/j.brainres.2012.05.044

Yan, J., Liu, Q., Dua, Y., Hsieh, Y., Liu, Y., Yao, R., et al. (2013). Activating glial glutamate transporter GLT-1 during ischemia: an in vivo study in the hippocampal CA1 of normal mice and mutant mice lacking GLT-1. *J. Neurosci.*, 33, 10569–10578. doi: 10.1523/JNEUROSCI.0377-13.2013

Ye, R., Yang, Q., Kong, X., Han, J., Zhang, X., Zhang, Y., et al. (2011a). Ginsenoside Rd attenuates early oxidative damage and sequential inflammatory response after transient focal ischemia in rats. *Neurochem. Res.* 35, 391–398. doi: 10.1007/s11064-010-0235-x

Ye, R., Kong, X., Han, J., Yang, Q., Zhang, Y., et al. (2011b). Ginsenoside Rd attenuates mitochondrial dysfunction and sequential apoptosis after transient focal ischemia. *Neuroscience* 178, 169–180. doi: 10.1016/j.neuroscience.2011.01.007

Yeh, T. H., Hwang, H. M., Chen, J. J., Wu, T. L., Li, A. H., and Wang, H. L. (2005). Glutamate transporter function of rat hippocampal astrocytes is impaired following the global ischemia. *Neurobiol. Dis.* 18, 478–483. doi: 10.1016/j.nbd.2004.12.011

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received 27 September 2013, accepted 24 November 2013, published online: 11 December 2013.

Citation: Zhang, X., Shi, M., Bjørås, M., Wang, W., Zhang, G., Han, J., Liu, Z., Zhang, Y., Wang, B., Chen, J., Zhu, X., and Zhao, G. (2013) Ginsenoside Rd promotes glutamate clear-ance by up-regulating glial glutamate transporter GLT-1 via PI3K/AKT and ERK1/2 pathways. *Front. Pharmacol.* 4:222. doi: 10.3389/fphar.2013.00222

This article was submitted to Cardiovascular and Smooth Muscle Pharmacology, a section of the journal Frontiers in Pharmacology. Copyright © 2013 Zhang, Shi, Bjørås, Wang, Zhang, Han, Liu, Zhang, Wang, Chen, Zhu, Xiong and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.